Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Reuters survey: Out of 104 economists, 94 expect the Federal Reserve to keep the federal funds rate unchanged in the 3.50%-3.75% range in September (compared to 95 holding this view in the July survey). Out of 104 economists, 80 expect the Federal Reserve to keep the federal funds rate in the 3.50%-3.75% range through 2026 (compared to 78 with this view in the July survey).

Reuters survey: Out of 104 economists, 94 expect the Federal Reserve to keep the federal funds rate unchanged in the 3.50%-3.75% range in September (compared to 95 holding this view in the July survey). Out of 104 economists, 80 expect the Federal Reserve to keep the federal funds rate in the 3.50%-3.75% range through 2026 (compared to 78 with this view in the July survey).

智通财经智通财经2026/08/17 11:16
Show original

Reuters Survey: Out of 104 economists, 94 expect the Federal Reserve to keep the federal funds rate unchanged in the 3.50%-3.75% range in September (95 held this view in the July survey). Among the 104 economists, 80 expect the Federal Reserve to maintain the federal funds rate in the 3.50%-3.75% range in 2026 (78 held this view in the July survey).

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds